T-cell Non-Hodgkin Lymphoma (T-cell NHL)
Showing 1 - 25 of >10,000
LY007 for r/r B-NHL and Exploration of Novel CAR-T Translational
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- (no location specified)
Sep 19, 2023
Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),
Not yet recruiting
- Non Hodgkin's Lymphoma
- TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
- +2 more
-
Beijing, China
- +2 more
Aug 23, 2023
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- BTK inhibitor
- PD-1 inhibitor
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023
Relapsed or Refractory Mantle Cell Lymphoma (MCL) Trial in Duarte (BAFFR-CAR T cells)
Recruiting
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- BAFFR-CAR T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Oct 18, 2022
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Cyclophosphamide injection
- +2 more
-
Charleston, South CarolinaHollings Cancer Center at Medical University of South Carolina
Jan 18, 2023
NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)
Not yet recruiting
- NK/T Cell Lymphoma
- +2 more
-
Guangzhou, Guangdong, China
- +1 more
Jan 12, 2023
Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)
Recruiting
- Non-hodgkin Lymphoma,B Cell
- Autologous CD19-STAR-T cell
- +2 more
-
Beijing, Beijing, China
- +1 more
Nov 21, 2022
Non Hodgkin Lymphoma Trial in Aurora (UCD19 CAR T Cells)
Active, not recruiting
- Non Hodgkin Lymphoma
- UCD19 CAR T Cells
-
Aurora, ColoradoUniversity of Colorado Hospital
Sep 1, 2022
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)
Not yet recruiting
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
- (no location specified)
Mar 23, 2023
CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Suzhou (ThisCART19A with Dose Level 1, ThisCART19A with Dose Level
Recruiting
- CAR
- +2 more
- ThisCART19A with Dose Level 1
- ThisCART19A with Dose Level 2
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jan 18, 2023
Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial in Miami (Mosunetuzumab,
Not yet recruiting
- Refractory Non-Hodgkin Lymphoma
- +2 more
- Mosunetuzumab
- +2 more
-
Miami, FloridaUniversity of Miami
Aug 3, 2022
Lymphoma, Non-Hodgkin, Lymphoma, T-Cell Trial in Najing (Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection)
Recruiting
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
-
Najing, Jiangsu, ChinaJiangsu Provincial People's Hospital
Sep 26, 2022
B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma Trial in Aurora (CD19CAR-CD3Zeta-4-1BB-Expressing Autologous
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B-cell Non Hodgkin Lymphoma
- CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
-
Aurora, ColoradoChildren's Hospital Colorado
Nov 9, 2022
Non-Hodgkin Lymphoma Trial in Dallas (Focal radiation therapy (RT))
Recruiting
- Non-Hodgkin Lymphoma
- Focal radiation therapy (RT)
-
Dallas, TexasUT Southwestern Medical Center
Jul 8, 2022
B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)
Recruiting
- B-cell Non Hodgkin Lymphoma
- regimen with BTK inhibitor +Anti-CD19 CAR T cells
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023
B-Cell Non-Hodgkin Lymphoma, DLBCL, Mantle Cell Lymphoma Trial in Duarte (Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous
Not yet recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Anti-CD19-CAR CMV-specific T-lymphocytes
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 28, 2022
Advanced Malignancies Trial in Beijing (1A46 Drug Substance)
Not yet recruiting
- Advanced Malignancies
- 1A46 Drug Substance
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Aug 4, 2023
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States
Completed
- Non-Hodgkin's Lymphoma, Relapsed
- +8 more
- PBCAR20A
- +2 more
-
Duarte, California
- +4 more
Jan 4, 2023
B-cell Non-Hodgkin's Lymphoma Trial in Beijing (CD19/CD20 Dual-CAR-T cells)
Suspended
- B-cell Non-Hodgkin's Lymphoma
- CD19/CD20 Dual-CAR-T cells
-
Beijing, Beijing, ChinaBeijing Tsinghua Changgung Hospital
Jan 29, 2022
Hairy Cell and Other Leukemias, and to Develop Recombinant
Recruiting
- Hairy Cell Leukemia (HCL)
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022
Non-Hodgkin's Lymphoma Trial in Hangzhou (ThisCART19A)
Recruiting
- Non-Hodgkin's Lymphoma
- ThisCART19A
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Apr 21, 2022
Diffuse Large B Cell Lymphoma (DLBCL) Trial in Denver, Nashville (bbT369)
Recruiting
- Diffuse Large B Cell Lymphoma (DLBCL)
- bbT369
-
Denver, Colorado
- +1 more
Feb 10, 2022